KALARIS THERAPEUTICS, INC. Operating Income
KALARIS THERAPEUTICS, INC. (KLRS) reported Operating Income of -$12.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$12.39M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$11.83M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$10.80M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$12.74M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$46.15M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$51.73M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$199.90M.
- KALARIS THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$171.20M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$12.39M 10-Q · filed 2026-08-11 | -$24.22M 10-Q · filed 2026-08-11 | -$35.02M derived: sum of 3 quarters · filed 2026-08-11 | -$47.76M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$11.83M 10-Q · filed 2026-05-12 | -$22.63M derived: sum of 2 quarters · filed 2026-05-12 | -$35.38M derived: sum of 3 quarters · filed 2026-05-12 | -$47.63M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$23.54M derived: sum of 2 quarters · filed 2026-03-17 | -$35.80M derived: sum of 3 quarters · filed 2026-08-11 | -$46.15M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | -$12.74M 10-Q · filed 2025-11-12 | -$25.00M derived: sum of 2 quarters · filed 2026-08-11 | -$35.35M 10-Q · filed 2025-11-12 | -$42.48M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$12.26M 10-Q · filed 2026-08-11 | -$22.61M 10-Q · filed 2026-08-11 | -$29.74M derived: sum of 3 quarters · filed 2026-08-11 | -$67.59M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$10.35M 10-Q · filed 2026-05-12 | -$17.49M derived: sum of 2 quarters · filed 2026-05-12 | -$55.34M derived: sum of 3 quarters · filed 2026-05-12 | -$59.52M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$7.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$44.98M derived: sum of 2 quarters · filed 2026-03-17 | -$49.17M derived: sum of 3 quarters · filed 2026-03-17 | -$51.73M 10-K · filed 2026-03-17 | -$65.44M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | -$37.85M 10-Q · filed 2025-11-12 | -$5.72M 10-Q · filed 2024-11-12 | -$42.04M derived: sum of 2 quarters · filed 2025-11-12 | -$44.60M 10-Q · filed 2025-11-12 | -$45.79M 10-Q · filed 2024-11-12 | -$107.00M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$4.19M 10-Q · filed 2025-08-13 | -$7.77M 10-Q · filed 2024-08-09 | -$6.75M 10-Q · filed 2025-08-13 | -$40.07M 10-Q · filed 2024-08-09 | -$69.16M derived: sum of 3 quarters · filed 2025-08-13 | -$116.12M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$2.56M 10-Q · filed 2025-05-14 | -$32.30M 10-Q · filed 2024-05-13 | -$64.97M derived: sum of 2 quarters · filed 2025-05-14 | -$111.93M derived: sum of 3 quarters · filed 2025-05-14 | -$159.23M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$62.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$109.37M derived: sum of 2 quarters · filed 2025-03-07 | -$156.67M derived: sum of 3 quarters · filed 2025-03-07 | -$199.90M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | -$46.96M 10-Q · filed 2024-11-12 | -$94.27M derived: sum of 2 quarters · filed 2024-11-12 | -$137.50M 10-Q · filed 2024-11-12 | -$177.93M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$47.30M 10-Q · filed 2024-08-09 | -$90.53M 10-Q · filed 2024-08-09 | -$130.97M derived: sum of 3 quarters · filed 2024-08-09 | -$173.92M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | -$43.23M 10-Q · filed 2024-05-13 | -$83.67M derived: sum of 2 quarters · filed 2024-05-13 | -$126.61M derived: sum of 3 quarters · filed 2024-05-13 | -$171.24M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$40.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$83.38M derived: sum of 2 quarters · filed 2024-03-15 | -$128.01M derived: sum of 3 quarters · filed 2024-03-15 | -$171.20M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$42.95M 10-Q · filed 2023-11-02 | -$87.57M derived: sum of 2 quarters · filed 2023-11-02 | -$130.77M 10-Q · filed 2023-11-02 | -$186.56M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$44.62M 10-Q · filed 2023-08-03 | -$87.82M 10-Q · filed 2023-08-03 | -$143.61M derived: sum of 3 quarters · filed 2023-08-03 | -$189.12M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$43.19M 10-Q · filed 2023-05-04 | -$98.99M derived: sum of 2 quarters · filed 2023-05-04 | -$144.49M derived: sum of 3 quarters · filed 2023-05-04 | -$182.15M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | -$55.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$101.30M derived: sum of 2 quarters · filed 2023-02-15 | -$138.96M derived: sum of 3 quarters · filed 2023-02-15 | -$169.82M 10-K · filed 2023-02-15 | ||||
| 2021-09-30 | -$45.50M 10-Q · filed 2022-11-03 | -$83.16M derived: sum of 2 quarters · filed 2022-11-03 | -$114.02M 10-Q · filed 2022-11-03 | -$139.44M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$37.66M 10-Q · filed 2022-08-04 | -$68.52M 10-Q · filed 2022-08-04 | -$93.93M derived: sum of 3 quarters · filed 2022-08-04 | -$117.83M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$30.86M 10-Q · filed 2022-05-05 | -$56.28M derived: sum of 2 quarters · filed 2022-05-05 | -$80.18M derived: sum of 3 quarters · filed 2022-05-05 | -$92.33M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | -$25.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$49.32M derived: sum of 2 quarters · filed 2022-02-10 | -$61.47M derived: sum of 3 quarters · filed 2022-02-10 | -$71.31M 10-K · filed 2022-02-10 | ||||
| 2020-09-30 | -$23.90M 10-Q · filed 2021-11-05 | -$36.05M derived: sum of 2 quarters · filed 2021-11-05 | -$45.89M 10-Q · filed 2021-11-05 | -$55.40M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | -$12.15M 10-Q · filed 2021-08-06 | -$21.99M 10-Q · filed 2021-08-06 | -$31.50M derived: sum of 3 quarters · filed 2021-08-06 | -$39.98M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | -$9.84M 10-Q · filed 2021-05-06 | -$19.34M derived: sum of 2 quarters · filed 2021-05-06 | -$27.82M derived: sum of 3 quarters · filed 2021-05-06 | -$33.77M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | -$9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$17.98M derived: sum of 2 quarters · filed 2021-02-12 | -$23.93M derived: sum of 3 quarters · filed 2021-02-12 | -$26.70M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | -$8.48M 10-Q · filed 2020-11-10 | -$14.42M derived: sum of 2 quarters · filed 2020-11-10 | -$17.20M 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | -$5.95M 10-Q · filed 2020-09-02 | -$8.72M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |